Last reviewed · How we verify
CD19t-haNK suspension — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
CD19t-haNK suspension (CD19t-haNK suspension) — ImmunityBio, Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| CD19t-haNK suspension TARGET | CD19t-haNK suspension | ImmunityBio, Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- CD19t-haNK suspension CI watch — RSS
- CD19t-haNK suspension CI watch — Atom
- CD19t-haNK suspension CI watch — JSON
- CD19t-haNK suspension alone — RSS
Cite this brief
Drug Landscape (2026). CD19t-haNK suspension — Competitive Intelligence Brief. https://druglandscape.com/ci/cd19t-hank-suspension. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab